Certificates of Supplementary Protection for Drugs
Certificates of supplementary protection give innovators up to two extra years of patent-like rights for a new medicinal ingredient. Eligibility depends on a first Canadian approval, a qualifying patent claim, a timely Canadian submission and an application within 120 days.

Key takeaways
- A CSP adds up to two years of protection after the patent's normal term ends.
- Only the first authorization for a medicinal ingredient qualifies; salts, esters and polymorphs do not count as new.
- Apply within 120 days of the notice of compliance or of patent grant, whichever applies.
- The Canadian submission must generally follow a first filing in the EU, US, UK, Japan, Switzerland or Australia within 12 months.
- Making the ingredient for export from Canada does not infringe a CSP.
Certificates of supplementary protection: the short answer
Certificates of supplementary protection (CSPs) give pharmaceutical innovators up to two additional years of patent-like protection for a new medicinal ingredient, to compensate for time lost in research and regulatory approval. They were introduced by amendments to the Patent Act (ss. 104 to 134) that came into force in September 2017 as part of Canada's implementation of CETA.
A CSP is issued by the Minister of Health, attaches to an eligible patent, and takes effect when that patent's normal 20-year term expires. Eligibility is strict: the drug must contain a medicinal ingredient approved in Canada for the first time, the patent must claim it in a prescribed way, and the Canadian submission and CSP application must be filed on time.

For innovators, certificates of supplementary protection can be worth more than any other single life-cycle tool, because they extend exclusivity at the end of a product's patent life, when sales are usually highest. For generic and biosimilar manufacturers, CSPs define the real market entry date and are listed on the PM(NOC) register like patents. This article explains eligibility, timing, the scope of protection and the ways CSPs can be challenged.
Eligibility for a certificate of supplementary protection
Under s. 106(1) of the Patent Act, a patentee may apply for a CSP, on payment of the prescribed fee, if all of the following conditions are met:
- the patent is not void and meets prescribed requirements (under the Certificate of Supplementary Protection Regulations, it must be in force);
- the patent application was filed on or after 1 October 1989;
- the patent pertains in a prescribed manner to the medicinal ingredient, or combination of medicinal ingredients, in a drug for which an authorization for sale (a notice of compliance) was issued after the regime came into force;
- the authorization is the first one issued for that medicinal ingredient or combination;
- no other CSP has been issued for that medicinal ingredient or combination; and
- if a marketing application was filed first in a prescribed foreign jurisdiction, the Canadian application for the authorization for sale was filed within the prescribed period after that first foreign filing.
Eligible patent claims
The Regulations set out the ways a patent may "pertain" to the medicinal ingredient. In summary, the patent must contain a claim for the medicinal ingredient or combination contained in the approved drug, a claim for the ingredient or combination as obtained by a specified process, or a claim for a use of the ingredient or combination. Formulation and dosage-form claims do not qualify on their own, which is a significant difference from PM(NOC) listing rules.
New medicinal ingredient and prescribed variations
The "first authorization" condition means a new salt, ester, enantiomer, solvate, polymorph or post-translational modification of an already-approved ingredient does not qualify. The Regulations treat these prescribed variations as the same medicinal ingredient. Only one CSP can issue for each medicinal ingredient or combination, and a CSP is treated as having been issued for this purpose even if it is later held invalid or never takes effect (s. 106(2)).
Timing rules and the timely submission requirement
Two timing rules catch applicants out.
| Requirement | Source | Rule |
|---|---|---|
| CSP application deadline | Patent Act s. 106(3); CSP Regulations s. 6(2) | Within 120 days after the authorization for sale is issued (if the patent was granted on or before that day) or after the patent is granted (if granted later) |
| Timely Canadian drug submission | Patent Act s. 106(1)(f); CSP Regulations s. 6(1) | If a marketing application was first filed in the EU or an EU member state, the US, Australia, Switzerland, Japan or the UK, the Canadian submission must follow within the prescribed period, generally 12 months |
| Late-term filing bar | Patent Act s. 106(4) | No application may be filed within the prescribed period before the patent's normal term expires |
| Priority among patents | Patent Act s. 108 | Patents granted on or before the authorization rank ahead of patents granted later |
The timely submission rule has the largest strategic effect. Global launch sequencing that leaves Canada well behind the first major market can make a product ineligible for a CSP, regardless of how innovative it is. Regulatory and patent teams should agree a Canadian filing date early in the global development plan. A transitional 24-month period applied during the first year of the regime.
Calendar the 120-day CSP deadline from the date of the notice of compliance, not from the date the product launches. If several patents could support a CSP, choose the one most likely to survive validity challenges, since only one certificate can issue per medicinal ingredient.
How long a CSP lasts
Under s. 116(3), the term of a CSP is the period from the filing date of the patent application to the date the authorization for sale was issued, minus five years, up to a maximum of two years. If the patentee also holds the authorization and the Minister considers that the patentee's failure to act caused unjustified delay in obtaining approval, the term can be reduced by that period (s. 116(4)). If the calculation is zero or negative, the certificate never takes effect (s. 116(5)).
The CSP takes effect on the expiry of the patent's normal term under s. 44, but only if the patent remains valid until then (s. 116(2)). Section 116(6) confirms that a CSP runs concurrently with any additional term granted for patent office delay under s. 46.1, so the two do not stack. See our insight on patent term adjustment.
Illustration: a patent application is filed in January 2012 and the notice of compliance issues in January 2021. The period is nine years; minus five years gives four years, capped at two. The CSP would add two years after the patent expires in January 2032.
Scope of protection and the export exception
A CSP gives the same rights as the patent, but only for making, constructing, using and selling a drug that contains the medicinal ingredient or combination set out in the certificate, alone or with other ingredients (s. 115(1)). It does not extend the patent's protection to other products the patent might cover. Under s. 115(2), it is not an infringement of the CSP to make, construct, use or sell the medicinal ingredient or combination for the purpose of export from Canada. That export exception lets Canadian generic manufacturers produce for foreign markets during the CSP term.
A CSP cannot be transferred separately from the patent it sets out (s. 118); transferring the patent, or part of it, transfers the corresponding certificate. Licences and assignments should therefore address CSP rights expressly, including who will apply for the certificate, who controls enforcement during its term, and whether royalties continue to be payable after the patent's normal term ends while the certificate is in force.
Certificates of supplementary protection and the PM(NOC) Regulations
CSPs can be added to the patent register under the PM(NOC) Regulations where the underlying patent is listed in respect of the same submission. A generic or biosimilar manufacturer referencing the innovator's product must address listed CSPs as well as patents, and an innovator can bring a section 6 action to enforce them. See our insight on section 6 actions.
Refusals, appeals and validity challenges
The Minister of Health may refuse an application that does not meet the s. 106 requirements and must give reasons (s. 107(2)). Refusals can be challenged by judicial review in the Federal Court, so applicants should build a full record with the original application. After issuance, a CSP or any claim in the underlying patent may be declared invalid or void by the Federal Court under s. 125, including on the basis that the certificate was issued despite non-compliance with s. 106(1) as it stood at issuance. Generic and biosimilar manufacturers commonly attack both the patent and the CSP, and sometimes argue that the medicinal ingredient was not new because a variation had been approved earlier.
Disputes over certificates of supplementary protection can arise over whether an ingredient is genuinely new, whether a combination differs from previously approved single ingredients, and whether a patent claim "pertains" to the approved drug. Applicants should prepare their CSP applications with that litigation in mind, documenting why each requirement is satisfied and keeping evidence of foreign filing dates, approval history and the relationship between the claims and the approved drug.
Biologics, combinations and new uses
Certificates of supplementary protection are available for biologics as well as small molecules, since the test turns on the medicinal ingredient rather than the type of drug. For biologics, the prescribed variations include in vivo or in vitro post-translational modifications, so a modified version of an approved protein will often be treated as the same medicinal ingredient and will not support a second certificate.
Combination products raise their own questions. A combination of medicinal ingredients can qualify as a "first" authorization if that combination has not been approved before, even where each ingredient has been approved separately, but the patent must claim the combination of all the medicinal ingredients in the approved drug, and only one certificate can issue for that combination. New indications for an existing ingredient do not create a new medicinal ingredient, so a second-use patent cannot support a CSP for an ingredient that was already authorized. Innovators with pipelines of combinations and new indications should therefore plan which product will carry the CSP and which patent will support it.
Strategy for innovators and generics
For innovators, certificates of supplementary protection should be built into product planning from the first global regulatory filing. The main levers are the timing of the Canadian submission, the choice of patent, the drafting of claims that will "pertain" to the approved ingredient, and avoiding regulatory delay that could reduce the term. For generics and biosimilars, the main questions are whether the CSP is valid, whether it covers their product, and whether export manufacturing is possible during its term. Both sides should model certificates of supplementary protection alongside data protection under the Food and Drug Regulations and patent term adjustment. See our pages on patents and life sciences and health.
How TRW & Co helps
We advise innovators, generic and biosimilar manufacturers and investors on certificates of supplementary protection in Canada. We assess eligibility and timing during global regulatory planning, prepare and review CSP applications with the client's regulatory team, respond to refusals, evaluate validity and scope, and plan PM(NOC) and export strategies. Litigation in the Federal Court is conducted with Canadian-licensed counsel, and patent prosecution is handled with registered patent agents. To discuss a product, contact us. This article is general information, not legal advice.
Frequently asked questions
How long does a certificate of supplementary protection last?
The term equals the period from the patent application's filing date to the date of the authorization for sale, minus five years, up to a maximum of two years. It can be reduced for unjustified delay by the patentee in obtaining approval, and it runs concurrently with any patent term adjustment.
What is the deadline to apply for a CSP?
Within 120 days after the notice of compliance issues if the patent was granted on or before that day, or within 120 days after the patent is granted if it issued later. An application cannot be filed in the prescribed period just before the patent's normal term expires.
Can a new salt or formulation get a CSP?
No. The Regulations treat salts, esters, enantiomers, solvates, polymorphs and certain other variations as the same medicinal ingredient, so they do not qualify as a first authorization. Formulation claims alone also do not make a patent eligible.
What is the timely submission requirement?
If a marketing application was filed first in a prescribed jurisdiction, being the EU or a member state, the US, Australia, Switzerland, Japan or the UK, the Canadian application for authorization must have been filed within the prescribed period, generally 12 months, after that first foreign filing.
Can a generic manufacturer make the drug in Canada during a CSP?
Yes, for export. Section 115(2) of the Patent Act provides that making, constructing, using or selling the medicinal ingredient for the purpose of export from Canada does not infringe the CSP. Sales in Canada remain restricted during the term.
Sources
General information only, not legal advice. References to statutes, courts and authorities describe published law and practice at the date shown.


